Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
ticagrelor
The First People's Hospital of Lianyungang
Inflammation
1 trial -
ticagrelor + ASA
Peking University Third Hospital
Cerebrovascular Accident
1 trial -
transdermal nicotine replacement therapy
BRIGHT MINDS BIOSCIENCES INC.
Smoking
1 trial -
trastuzumab [Herceptin]
Hoffmann-La Roche
Gastric Cancer
1 trial -
umeclidinium 62.5 µg and vilanterol 25 µg
Theravance Biopharma Ireland Umited
COPD (Chronic Obstructive Pulmonary Disease)
1 trial -
0 ul of ondansetron
Hospital Authority, Hong Kong
Blood Coagulation Disorder
1 trial -
10% N2O
BRIGHT MINDS BIOSCIENCES INC.
Opioid-Related Disorders
1 trial -
18F-P3BZA
Xijing Hospital
Melanoma
1 trial -
30% Nitrous oxide
BRIGHT MINDS BIOSCIENCES INC.
Opioid-Related Disorders
2 trials -
4D
4D Molecular Therapeutics
Dietary Supplementation
1 trial -
5-gene classification model
Hospital Authority, Hong Kong
ABO Blood Type Incompatible Kidney Transplantation
1 trial -
68Ga-Her2-affibody
The First People's Hospital of Lianyungang
Neoplasms
1 trial -
7 g Ispaghula
IRONWOOD PHARMACEUTICALS INC
Healthy
1 trial -
75 mg acetylsalicylic acid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Preeclampsia
1 trial -
99mTc-pyrophosphate Scintigraphy
Alnylam Netherlands B.V.
Transthyretin Amyloidosis
1 trial -
A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).
The First People's Hospital of Lianyungang
Neuromuscular Blockade
1 trial -
A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively.
The First People's Hospital of Lianyungang
Anal Fistula
1 trial -
ATRA+Venetoclax+Azacitidine
The First People's Hospital of Lianyungang
AML, Adult
1 trial -
Abbreviated non-contrast MRI of the liver
Hospital Authority, Hong Kong
Hepatocellular Carcinoma
1 trial -
Acalabrutinib
The First People's Hospital of Lianyungang
Chronic Lymphocytic Leukemia
1 trial -
Adjustment of Antiplatelet Drugs
The First People's Hospital of Lianyungang
Intracranial Aneurysm
1 trial -
Alcohol(oral) and placebo
BRIGHT MINDS BIOSCIENCES INC.
Alcohol Drinking
1 trial -
Amino acid based formula
United Therapeutics Europe Ltd
Cow Milk Allergy
1 trial -
Amivita
Wujin People's Hospital
Amyotrophic Lateral Sclerosis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources